LifeMine Therapeutics has raised $263 million to advance a new organ-transplant drug discovered by mining the genomes of fungi.

The haul spans two rounds — a $75 million Series D in late 2025 and a $188 million Series E led by Milky Way Investments, with backers including Bezos Expeditions, Gates Frontier, GV, RA Capital and Arch Venture Partners — bringing total private funding to about $580 million. Announced August 6, 2026.

The drug

Lead candidate LIFE-001 came from LifeMine’s systematic database of fungal genomes. It inhibits calcineurin — the same enzyme targeted by long-used transplant drugs — but binds a previously unknown site and, importantly, does not penetrate the brain and peripheral tissues, which the company says should make it safer than existing options.

It is designed as a long-acting injectable to keep immune suppression steady.

Why calcineurin, and why its inhibitors are a problem

Calcineurin inhibitors have anchored transplant immunosuppression for decades because they work: blocking the enzyme prevents T cells activating, which is the central event in rejection.

Their toxicity is equally well established. Kidney damage is the most consequential — the drugs are progressively nephrotoxic, so a kidney-transplant recipient is treated with an agent that slowly damages the organ they received. Neurological effects range from tremor to seizures and confusion. Metabolic effects include hypertension and new-onset diabetes.

Transplant medicine has long accepted this trade-off because the alternative is losing the graft. It is a genuinely unsatisfactory position rather than a resolved one.

Why tissue distribution is the design choice

The claim that the drug does not reach brain and peripheral tissues is the whole therapeutic proposition, and it follows a coherent logic.

Calcineurin is not confined to immune cells. It is present in neurons, kidney tubules and elsewhere, performing unrelated functions — and the toxicity of existing drugs comes from inhibiting it in those places, not from the immunosuppression itself.

A drug excluded from those compartments could therefore retain the immune effect while removing much of the harm. Achieving that reliably is difficult, and whether LIFE-001 does so in humans is what the clinical programme must establish.

The novel binding site is what makes the distribution possible: a different chemical scaffold has different physical properties, and those properties determine which tissues a molecule enters.

Fungi as a drug source

Fungi have a storied history in medicine — the same starting point that gave the world penicillin, the first statin and the transplant drug cyclosporine.

The reason is ecological. Fungi compete with bacteria and other organisms chemically rather than physically, and have evolved enormous numbers of bioactive compounds to do it. Those molecules are shaped by selection to interact with biological targets, which makes them a better starting point than randomly synthesised chemistry.

Cyclosporine is the directly relevant precedent: a fungal compound that made modern organ transplantation practical.

What genome mining changes

LifeMine, founded by veteran biotech entrepreneur Greg Verdine, is betting modern genome mining can systematically surface more.

Historically fungal drugs were found by culturing organisms and testing what they secreted — which finds only compounds a fungus produces under laboratory conditions. Most biosynthetic gene clusters stay silent in culture, so most of the chemistry was never seen.

Sequencing genomes reveals those clusters directly. The gene sequences indicate what kind of molecule would be produced, and the compound can be pursued deliberately rather than waiting for the organism to make it — which converts a sampling problem into a search problem.

Where it stands

LIFE-001 is in a Phase 1 safety study, with Phase 2 results in kidney-transplant recipients expected in 2028 and early islet-cell-transplant data by the end of 2027.

Why transplant immunosuppression has changed so little

Calcineurin inhibitors have remained standard for roughly four decades, and that stability reflects the difficulty of improving on them rather than satisfaction with them.

Any replacement must clear an unusually high bar. Rejection is catastrophic and often irreversible, so a new agent cannot be marginally less effective in exchange for better tolerability. Trials must therefore show non-inferiority in graft survival, requiring large studies over long follow-up.

The comparator is also cheap. Existing calcineurin inhibitors are long off patent and cost little, so a new drug must justify a substantial price premium on safety grounds alone — and payers must be persuaded that avoided kidney damage years later is worth paying for now.

Several attempted alternatives have illustrated the risk. Agents avoiding calcineurin toxicity by working through other mechanisms have variously shown higher rejection rates or unexpected complications of their own.

Keeping the proven mechanism while changing where the drug goes is a more conservative bet than replacing the mechanism — which is likely why it attracted this much capital.

The islet-cell application is worth noting. Transplanting insulin-producing cells could treat type 1 diabetes, and the field has been constrained partly because lifelong immunosuppression is hard to justify for a condition manageable with insulin. A materially safer agent would change that calculation. Business news, not investment advice.